Title Page:

#### **Insulin-like growth factor 2 hypermethylation in peripheral blood leukocytes and colorectal**

#### **cancer risk and prognosis: a propensity score analysis of multiple-centre populations**

- **Short Title:** IGF2 and CRC risk and prognosis
- 5 HongRu Sun<sup>1#</sup>, YanLong Liu<sup>2#</sup>, YuXue Zhang<sup>3</sup>, Yibaina Wang<sup>1</sup>, BinBin Cui<sup>2</sup>, YaShuang Zhao<sup>1\*</sup>, YuPeng Liu<sup>1\*</sup>

**Author affiliations:** 

- **HongRu Sun** (sunhongru\_1024@126.com), **Yibaina Wang** (zhulin\_vip@yeah.net), **YaShuang Zhao**
- 8 (zhao\_yashuang@263.net), and **YuPeng Liu** (liuyupeng@wmu.edu.cn), <sup>1</sup> Department of Epidemiology, Public Health
- College, Harbin Medical University, 157 Baojian Street, Harbin 150081, Heilongjiang Province, China;
- **YanLong Liu** (liuyanlong1979@163.com) and **BinBin Cui** (cuibinbin222@hotmail.com), <sup>2</sup> Department of Colorectal
- Surgery, The Third Affiliated Cancer Hospital of Harbin Medical University, 150 Haping Street, Harbin 150081,
- Heilongjiang Province, China;
- **13** YuXue Zhang (zhang yuxue@126.com), <sup>3</sup> Department of Hygiene Microbiology, Public Health College, Harbin Medical
- University, 157 Baojian Street, Harbin 150081, Heilongjiang Province, China;
- <sup>#</sup>These authors have contributed equally to this work and share first authorship.
- \*These authors have contributed equally to this work and share last authorship.
- \* **Corresponding Author**: **YuPeng Liu**, Ph.D., **Postal address**: 157# Baojian Street, Nangang District, Harbin 150081,
- Heilongjiang Province, China. **Telephone**: 86-(0)451-86611797, **Fax**: 86-(0)451-87502885, **E-mail**:
- liuyupeng@wmu.edu.cn; ORCID: 0000-0002-8652-1987.
- **Author Contributors: HRS** and **YLL** contributed equally to this work. **YPL** had full access to all of the data in the
- initial study and take responsibility for the integrity of the data and the accuracy of the data analysis. **YPL** and **YSZ**
- contributed to study conception and design. **YPL, HRS, YBNW** and **YXZ** contributed to DNA preparation and bisulfite
- modification. **YPL, HRS, YBNW**, and **YLL** contributed to MS-HRM. **YPL, HRS, YXZ,** and **YSZ** contributed to
- collection and assembly of data. **YSZ, BBC, YPL, HRS,** and **YLL** contributed to the analysis and interpretation of data.
- **YPL, YLL, BBC, YXZ** and **YSZ** contributed to sample collection. **YPL, HRS, YLL, YXZ** and **YSZ** contributed to the
- drafting of the initial versions of the manuscript. All authors contributed to the review and final approval of the
- manuscript. **YPL** and **YSZ** were responsible for study supervision.
- **Conflict of Interests:** All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts

of Interest. The authors have declared that no conflict of interest exists. The funders had no role in the design of the study;

in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the

results.

**Ethics approval**: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by

the Medical Ethics Committee of Harbin Medical University (1 Mar, 2014). All participants in the initial cohort provided

written informed consent. Informed consent was obtained from all subjects involved in the initial cohort. Written

- informed consent has been obtained from the patients to publish this paper.
- **Grant support:** This work was supported by the China Postdoctoral Science Foundation (grant number 2018M641875 to
- **YPL**); the Natural Science Foundation of Heilongjiang Province (grant number YQ2019H021 to **YPL**); the National

Natural Science Foundation of China (grant number 81473055 to **YSZ**), and by grant from the SCORE Foundation

(Y-MX2016-045 to **YLL**).

**Writing Assistance:** The authors thank American Journal Experts for English language polishing of the manuscript.

**Acknowledgments:** The authors thank the participants and staff of both the initial study and the validation studies from

the GEO and TCGA for providing data and their valuable contributions. The authors thank the GEO and TCGA databases

for the access to the validation datasets. The authors thank Dr. Carlotta Sacerdote (Città della Salute e della Scienza

University) and Dr. Giovanni Fiorito (University of Sassari) for providing critical help in validation stage. The authors

thank Professor Wei Chen (Tulane University) for critically reading this manuscript.

**Data Transparency Statement:** Authors are willing to share any data that are used in this work. The data that support

the findings of the initial study are included in the manuscript and supporting file. The raw datasets used in the validation

stage are publicly available on GEO (http://www.ncbi.nlm.nih.gov/geo/) and TCGA (CORD and READ)

(https://cancergenome.nih.gov/).

**Abbreviations:** body mass index (BMI), carcinoembryonic antigen (CEA), confidence intervals (CIs), colorectal cancer

- (CRC), CRC-specific survival (CSS), disease free survival (DFS), Gene Expression Omnibus (GEO), Harbin Medical
- University (HMU), hazard ratios (HRs), insulin-like growth factor 2 (IGF2), loss of imprinting (LOI),

methylation-sensitive high-resolution melting (MS-HRM), odd ratios (ORs), overall survival (OS), peripheral blood

leukocytes (PBLs), propensity score (PS), The Cancer Genome Atlas (TCGA).

- **Word counts:** Main Text **4918** words; Abstract **303** words; Figures **9**; Tables **1**; References **39**; Supplementary Files **6**
- **Keywords:** IGF2 hypermethylation; colorectal neoplasms; risk; prognosis; propensity score analysis

#### **ABSTRACT:** (**303** words)

**Background:** To comprehensively assess and validate the associations between insulin-like growth factor 2 (*IGF2*) gene methylation in peripheral blood leukocytes (PBLs) and colorectal cancer (CRC) risk and prognosis.

**Methods:** The association between *IGF2* methylation in PBLs and CRC risk was initially evaluated

in a case-control study and then validated in a nested case-control study and a twins' case-control

study, respectively. Meanwhile, an initial CRC patient cohort was used to assess the effect of *IGF2*

methylation on CRC prognosis and then the finding was validated in the EPIC-Italy CRC cohort and

TCGA datasets. A propensity score (PS) analysis was performed to control for confounders, and

extensive sensitivity analyses were performed to assess the robustness of our findings.

**Results:** PBL *IGF2* hypermethylation was associated with an increased risk of CRC in the initial

study (ORPS-adjusted, 2.57, 95% CI: 1.65 to 4.03, *P*<0.0001), and this association was validated using

two independent external datasets (ORPS-adjusted, 2.21, 95% CI: 1.28 to 3.81, *P*=0.0042 and

ORPS-adjusted, 10.65, 95% CI: 1.26 to 89.71, *P*=0.0295, respectively). CRC patients with IGF2

hypermethylation in PBLs had significantly improved overall survival compared to those patients

with IGF2 hypomethylation (HRPS-adjusted, 0.47, 95% CI: 0.29 to 0.76, *P*=0.0019). The prognostic

signature was also observed in the EPIC-Italy CRC cohort, although the HR did not reach statistical

significance (HRPS-adjusted, 0.69, 95% CI: 0.37 to 1.27, *P*=0.2359).

**Conclusions:** IGF2 hypermethylation may serve as a potential blood-based predictive biomarker for

the identification of individuals at high risk of developing CRC and for CRC prognosis.

**Funding:** This work was supported by the China Postdoctoral Science Foundation (grant number

2018M641875 to YPL); the Natural Science Foundation of Heilongjiang Province (grant number

YQ2019H021 to YPL); the National Natural Science Foundation of China (grant number 81473055

to YSZ), and by grant from the SCORE Foundation (Y-MX2016-045 to YLL).

**Clinical trial number:** Not applicable.

# **MAIN TEXT** (**4918** words)

## **1. INTRODUCTION**

Colorectal cancer (CRC) is the third-most common cancer in men and the second-most in women worldwide, with an estimated 1,931,590 newly diagnosed cases and 935,173 deaths in 2020, accounting for approximately 1 in 10 cancer cases and deaths.<sup>[12]</sup> In China, the number of CRC cases has rapidly increased since the 1980s, with an estimated 555,477 newly diagnosed patients and 286,162 deaths in 2020, accounting for approximately 30% of all annually diagnosed CRC cases and 89 CRC-related deaths worldwide.<sup>[2 3]</sup> The initiation and progression of CRC is multifactorial and gradual with progressive accumulation of both genetic and epigenetic abnormalities, including 91 aberrant DNA methylation and loss of imprinting  $(LOI)$ .<sup>[4-6]</sup> The insulin-like growth factor 2 (*IGF2*) gene is one of the first imprinted genes identified in humans. The IGF2 protein has a 93 tumour-promoting effect on existing colorectal neoplasia<sup>[7-10]</sup> and that LOI of IGF2 in either tissue or 94 peripheral blood leukocyte (PBL) samples is associated with an increased risk of CRC.<sup>[11 12]</sup> Furthermore, a recent cohort study showed a significant association between *IGF2* hypomethylation 96 in paraffin-embedded tissues and poor CRC prognosis.<sup>[13]</sup> However, no study has evaluated whether PBL IGF2 methylation, which can be determined using non-invasive techniques, is associated with CRC risk or prognosis.

We therefore performed this study to comprehensively assess the association between PBL IGF2 methylation status and CRC risk and prognosis. The propensity score (PS) method has been increasingly used to reduce the likelihood of confounding bias in observational studies. It is a powerful statistical tool to control for confounding bias and is often more practical and statistically more efficient than conventional strategies including covariate matching, stratified analysis, and 104 multivariate statistical analysis.  $[14 15]$  In this study, we used PS-based methods to assess the effect of PBL IGF2 methylation on the risk of developing CRC, and then further validated our findings using 106 external datasets from EPIC-Italy CRC cohort and  $GEO.<sup>[16-18]</sup>$  In addition, we used the same

- PS-based methods to assess the association between IGF2 methylation and CRC prognosis using
- CRC patient PBLs and tumour tissues, and then further validated our findings using external datasets
- 109 from EPIC-Italy CRC cohort and The Cancer Genome Atlas (TCGA).<sup>[17 19]</sup>

#### **2. METHODS**

- **2.1. Study design and participants**
- **2.1.1. Initial study**
- *2.1.1.1. IGF2 methylation in PBLs and CRC risk*

114 Descriptions of the study design and patient selection strategy have been published elsewhere.<sup>[20 21]</sup>

Briefly, this hospital-based case-control study included 281 primary sporadic CRC patients

diagnosed (from June 2004 to May 2005 and May 2007 to January 2008) at the Cancer Hospital of

- Harbin Medical University (HMU) and 147 CRC patients at the Second Affiliated Hospital of HMU
- (from October 2010 to December 2011) in Harbin, China (**Figure 1**). During the same time period,

428 cancer-free controls were selected from the Second Affiliated Hospital of HMU by individual

120 matching on gender and age  $(\pm 2 \text{ years})$ . The basic characteristics of the CRC cases and controls are

shown in **Supplementary File 1A**. All participants provided written informed consent prior to

participation in the study. Blood samples were collected before surgery for the CRC patients and

before any therapy for the controls. This study was approved by the Ethics Committee of HMU.

All CRC patients had operable stage I-IV CRC, and their CRC diagnosis was histologically confirmed by a senior surgeon (YYL). Patients with adenomatous polyposis coli, who had a family 126 history of CRC in first-degree relatives according to the Amsterdam criteria,<sup>[22]</sup> or who received anti-cancer therapy before surgery were excluded.

*2.1.1.2. IGF2 methylation in PBLs and CRC prognosis* 

The 281 CRC patients diagnosed at the Cancer Hospital of HMU were all included in the final CRC

cohort, while the 147 CRC patients from the Second Affiliated Hospital of HMU were excluded

because of the lack of follow-up information. For each patient, extensive demographic, clinicopathological and treatment information were extracted from the electronic medical record system. All surgical operations were performed by the same surgical oncologists (BBC and YLL) and all patients had negative surgical margins. The basic characteristics of the CRC patients included in this cohort are shown in **Supplementary File 1B**. The primary outcomes were overall survival (OS) from CRC diagnosis to death and disease free survival (DFS) from CRC diagnosis to disease recurrence, metastasis, or death from CRC, whichever came first. Another outcome was CRC-specific survival (CSS), which was defined as the time from disease diagnosis to CRC-specific death. Outcomes were observed during the follow-up period through March 15, 2014 via an established protocol. Postoperative patients were followed up

at 3-6 months intervals for the first year and then annually. We used a telephone-delivery follow-up

questionnaire to collect information on the date and cause of death of the CRC patients. The recorded

date and cause of death of the CRC patients were validated using the medical certification of death

and the Harbin death registration system. Of the 281 eligible CRC patients included in this analysis,

- 127 died, 120 remained alive and 34 were lost to follow-up.
- *2.1.1.3. IGF2 methylation in tumour tissues and CRC prognosis*

Fresh tumour tissues were collected during surgery from the CRC patients treated at the Cancer

Hospital of HMU, with written consent being obtained prior to surgery. Among the 298 eligible CRC

patients included in this analysis, 124 died, 141 remained alive and 32 were lost to follow-up. In all,

185 paired tumour tissue and PBL samples were obtained from the same patients.

*2.1.1.4. Sample size*

- The sample size was estimated using PASS version 11.0.7 (NCSS LLC., USA). To assess whether
- aberrant methylation of insulin-like growth factor 2 (IGF2) in peripheral blood leukocytes (PBLs) is
- associated with the risk of developing colorectal cancer (CRC) in our present case-control study, we

estimated the sample size according to a logistic regression model. A sample size of 652 participants was needed to achieve 90% power (at the 5% level of statistical significance) in order to detect an odds ratio (OR) of 1.8 or more with a 20% prevalence in the control group. In addition, taking into consideration incomplete questionnaires and the failure rate for MS-HRM detection, we included 159 approximately 20% more patients and finally targeted a total sample size of 800 participants ( $n = 400$ ) 160 for CRC patients and controls, respectively).

To assess whether aberrant IGF2 methylation in PBLs is associated with CRC patient prognosis in our present cohort study, we estimated the sample size according to a Cox regression model. A sample size of 184 CRC patients was needed to achieve 80% power (at the 5% level of statistical significance) to detect a hazard ratio (HR) of 0.5 or 2.0 with an overall event rate of 50% in this cohort. In addition, taking into consideration incomplete questionnaires and the failure rate for MS-HRM detection, we included approximately 20% more patients and finally targeted a total 167 sample size of 221 CRC patients.

#### **2.1.2. Validation study**

A case-control study nested in the EPIC-Italy cohort (GSE51032) and a twins' case-control study (GSE89093) from the GEO were used to validate the association between PBL IGF2 methylation and CRC risk. We also used the EPIC-Italy CRC cohort and TCGA datasets (COAD and READ) to validate the relationship between IGF2 methylation in PBLs or tumour tissues and CRC prognosis, respectively. The basic characteristics of validation populations are shown in **Supplementary File 1**.

## **2.2. Methylation analysis**

Sample processing, DNA extraction and bisulfite modification were performed as described

176 previously.<sup>[20]</sup> Briefly, DNA was extracted from buffy coats and tumour tissues using a QIAamp

DNA Blood Mini Kit (Qiagen, Hilden, Germany, Cat#51106) and a DNeasy Blood & Tissue Kit

(Qiagen, Cat #69506), respectively. The DNA was then bisulfite-modified using an EpiTect Plus



# **2.3. Covariates, Missing data analysis and imputation**

All participants were interviewed face-to-face to complete a structured standard questionnaire, which 205 was partially adopted from Shu et al.<sup>[24]</sup> The questionnaire queried information on demographic characteristics, lifestyle factors (including family history, smoking, alcohol consumption, occupational physical activity), and diet. Dietary consumption over the past year was assessed using 208 a validated food frequency questionnaire (FFQ).<sup>[24]</sup> The FFQ included nine major food groups, which represented most of the common foods in Northeast China. The food items included barbecued foods, coarse grains, fish stewed with brown sauce, fresh fruits, fried foods, green vegetables, leftovers and 211 pork.

212 Questionnaire-derived covariates included: age  $(< 60, \ge 60)$ , gender (male, female), BMI  $(< 24,$ 

213  $\geq$  24), family history of cancer other than CRC in first-degree relatives (no, yes), occupational

214 physical activity (blue-collar, white-collar), smoking status (no, yes), and consumption of barbecued

215 foods (< 1,  $\geq$  1 times/week), coarse grains (< 50,  $\geq$  50 g/week), fish stewed with brown sauce (< 1,  $\geq$ 

216 1 times/week), fruits  $(< 2, > 2$  times/week), fried foods  $(< 1, > 1$  times/month), green vegetables (<

217  $100 \ge 100$  g/day), leftovers (< 1,  $\ge 1$  times/week) and pork (< 250,  $\ge 250$  g/week). All

218 questionnaire-derived variables were analysed via missing value analysis and were imputed via

219 multiple imputations as described in our previous study.<sup>[20]</sup>

# 220 **2.4. Statistical analysis**

Means and standard deviations were reported for continuous variables, while counts and frequencies were reported for categorical variables. Covariate differences between groups were compared using 223 the standardised differences method with a significant imbalance level of standardised difference  $\geq$ 25%. In the CRC risk analysis, we first categorised individuals into two groups according to the 225 optimal cut-off point for the IGF2 methylation level  $(\leq 1\%$  hypomethylation group;  $> 1\%$ hypermethylation group), which was determined using the receiver operating characteristic (ROC) curve and the Youden index method with case-control status as the dependent variable (0 for controls; 1 for cases). We then conducted univariate and multivariate logistic regression analyses and reported

odd ratios (ORs) and 95% confidence intervals (CIs) to assess the association between IGF2 methylation status and CRC risk. In the CRC prognosis analysis, the cut-off point for the IGF2 methylation level was also 1% using the same method with overall survival time as the dependent variable (0 for less than median survival time; 1 for longer than or equal to median survival time). According to this cut-off point, CRC patients were categorised into IGF2 hypomethylation and IGF2 hypermethylation groups (206 and 75 cases, respectively). Kaplan-Meier curves and log-rank tests were used to compare OS, DFS or CSS between groups. The associations between IGF2 methylation and OS, DFS or CSS were estimated using univariate and multivariate Cox regression models and reported as hazard ratios (HRs) and 95% CIs. Two-sided statistical significance was defined as *P*<0.05. ROC analyses were performed with MedCalc version 15.4 (Ostend, Belgium) and all other statistical analyses were performed with SPSS Statistics version 23.0 (IBM, Inc., USA). To minimise group differences on covariates, we performed a PS-based analysis. In the CRC risk analysis, the PS was calculated with case-control status as the dependent variable using a multivariate logistic regression model that included demographic and lifestyle factors (**Supplementary File 2A**). In the survival analysis, the PS was calculated with IGF2 methylation as the dependent variable using a multivariate logistic regression model that included demographic and lifestyle factors and clinicpathological characteristics (**Supplementary File 2B**). To incorporate all 246 the patients in the analyses, we primarily employed the PS-adjustment method.<sup>[14]</sup> Additionally, several PS-based methods, including stratification by quintile of PS, weighting with inverse probability of treatment weights, and individual PS matching, were also performed as sensitivity analyses. For PS-stratification analyses, all patients were stratified by PS quintile. HRs for PS-stratified analyses were obtained by pooling effect estimates from each PS quintile. For PS-weighted analyses, each patient was weighted by the inverse probability of being in the higher versus lower IGF2

methylation groups; this method is known as weighting with inverse probability of treatment weights

(IPTW). The weight for each patient was calculated according to the method described by Robins 255 and Hernan:<sup>[25]</sup> Pt/PS and  $(1-Pt)/(1-PS)$  for patients in the IGF2 hypermethylation and hypomethylation groups, respectively; where Pt is the proportion of the patients with IGF2 hypermethylation in all participants. In addition to using PS as an adjustment or weighting factor in the analysis model, PS was also used for individual matching. PS matching was performed using a nearest-neighbour algorithm with a calliper of 0.2 (which means that the maximum allowable PS difference between groups was no larger than 20% of the standard deviation of PS).

#### **2.5. Sensitivity analysis**

To assess the robustness of our results, we performed extensively predefined sensitivity analyses. First, to evaluate the potential impact of the PS-adjusted confounders on our results in the initial study, we performed confounding RR analysis, which was defined as the ratio of the PS-adjusted 265 effect estimates and the unadjusted effect estimates.<sup>[26]</sup> To investigate whether potential residual confounders could impact the results, we calculated the E-value for PS-adjusted effect estimates and 267 the limit of the CI closest to the null.<sup>[27]</sup> Finally, we performed subgroup analyses according to the tumour location (colon or rectum), UICC stage, gender (female vs. male), age (≥60 vs. <60 years), 269 and body mass index (BMI,  $\geq$  24 vs. <24).

Additionally, we performed several post hoc sensitivity analyses. To test whether tumour load impacts IGF2 methylation level in PBLs, we assessed the associations between IGF2 methylation and UICC stage and serum carcinoembryonic antigen (CEA) level. We also tested whether PBL IGF2 methylation levels could have been impacted by leukocyte count and the percentage of certain subpopulations. In addition, to comprehensively determine the association between IGF2 methylation and CRC risk, we combined the results from the initial case-control and the validation studies using a meta-analysis method of random effect model. Finally, we explored whether PBL IGF2 methylation levels differ between the CRC patients included in the survival analysis and those excluded.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.27.22274374;](https://doi.org/10.1101/2022.04.27.22274374) this version posted April 28, 2022. The copyright holder for this preprint

#### **3. RESULTS**

## **3.1. IGF2 methylation in PBLs and CRC risk**

- As shown in **Figure 3A**, subjects with IGF2 hypermethylation (15.54%), compared to subjects with
- IGF2 hypomethylation (84.46%), had a significantly increased CRC risk (PS-adjusted OR, 2.57, 95%
- CI: 1.64-4.03; *P*<0.001). This association remained statistically significant even after subgroup
- analyses. Notably, stratified analyses showed a positive association only in UICC stage I-III but not
- in stage IV cancers.
- In the EPIC-Italy dataset, IGF2 hypermethylation was also significantly associated with an
- increased CRC risk (OR, 2.21, 95% CI: 1.28-3.81; *P*=0.004). Subgroup analyses showed the
- association was statistically significant in distal colon cancer, men, and older subjects (**Figure 3A**).
- Using the GSE89093 dataset, IGF2 hypermethylation was strongly associated with an increased risk
- of CRC or colon cancer alone. After pooling the results from these three datasets, the observed
- association was still significant (**Figure 3B**).

# **3.2. IGF2 methylation in PBLs and CRC prognosis**

The Kaplan-Meier survival curves for the PBL IGF2 hypermethylation and hypomethylation groups

- are shown in **Figure 4**. The median OS was 73 months (95% CI: 66-80 months) in the IGF2
- hypermethylation group versus 56 months (95% CI: 52-61 months) in the hypomethylation group.
- The OS rate was 75% (95% CI: 60-80%) in the IGF2 hypermethylation group versus 62% (95% CI:
- 297 50-57%) in the hypomethylation group (HR<sub>PS-adjusted</sub>, 0.47, 95% CI: 0.29-0.76; *P*=0.002). The CSS
- rate was 56% (95% CI: 45-68%) in the IGF2 hypermethylation group versus 38% (95% CI: 31-45%)
- in the hypomethylation group (HRPS-adjusted, 0.49, 95% CI: 0.30-0.80; *P*=0.004). The median DFS was
- 66 months (95% CI: 57-74 months) in the IGF2 hypermethylation group versus 52 months (95% CI:
- 48-57 months) in the hypomethylation group (HRPS-adjusted, 0.53, 95% CI: 0.32-0.85; *P*=0.009). Based
- on subgroup analyses, we found that the statistically significant association persisted in rectal cancers,

UICC stage I-III cancers, males, older, or normal body weight patients. In contrast, the effect estimates did not reach statistical significance in colon cancers, stage IV cancers, females, younger, and overweight or obese patients (**Table 1**).

Using the follow-up results of the 166 CRC patients from the EPIC-Italy cohort, we observed a

clear trend for a longer OS related with IGF2 hypermethylation, although the association was not

statistically significant. The univariate HR was 0.65 (95% CI: 0.35-1.19; *P*=0.164;), and after PS

adjustment, the HRPS-adjusted was 0.69 (95% CI: 0.37-1.27; *P*=0.236; K-M survival curves are shown

in **Figure 5**).

### **3.3. IGF2 methylation in tissues and CRC prognosis**

In our initial study, the association between IGF2 methylation in tumour tissues and CRC patient

survival did not reach statistical significance (**Figure 6A**), and this result was confirmed by the

TCGA dataset (**Figure 6B**). Using IGF2 mRNA expression data in tumour tissues, we found an

obvious negative correlation with IGF2 methylation (r=-0.24, *P*<0.001; **Figure 6C**). So we further

explored whether IGF2 mRNA expression levels impact the disease prognosis but found no

statistically significant association (**Figure 6D**).

# **3.4. Sensitivity analysis**

We repeated analyses using other PS-based methods and the results were consistent with the

PS-adjustment results (**Supplementary File 3**). Based on the confounding RR analysis (**Figure 7**),

we did not find any substantial differences between the PS-adjusted effect estimates and the

corresponding unadjusted effect estimates. Furthermore, the E-value analysis showed that our

findings in both the initial and validation studies appear to be very robust (**Supplementary File 4**).

We found no evidence for an obvious impact of UICC stages on IGF2 methylation in PBLs. Of

note, IGF2 hypermethylation was significantly more frequent in the CEA-low group than in the

CEA-high group (34.15% vs. 20.89%, *P*=0.013). We found no significant relationship between the

PBL IGF2 methylation levels and the leukocyte count or the percentages of certain leukocyte subpopulations. Finally, we analysed samples from 147 additional CRC patients that were excluded from the survival analysis and found no differences in their PBL IGF2 methylation levels compared to those of the 281 CRC patients included in the survival analysis (**Supplementary File 5)**.

# **4. DISCUSSION**

In this study, we first assessed the impact of the PBL IGF2 methylation status on the risk and prognosis of CRC. We found that individuals with IGF2 hypermethylation in their PBLs were at significantly higher risk of developing CRC than those with IGF2 hypomethylation. However, our findings showed better survival rates in CRC patients with PBL IGF2 hypermethylation compared to those in CRC patients with IGF2 hypomethylation.

In our initial case-control study, it is not possible to determine the aetiologically relevant time window of IGF2 methylation relative to CRC development. Fortunately, the prospective nature of the EPIC-Italy cohort is invaluable for confirming the temporal sequence of DNA methylation and CRC 340 onset and therefore helps to distinguish causal from consequential epigenetic changes.<sup>[28 29]</sup>. In this nested case-control study, blood samples from CRC patients were collected 0.02-14.40 years (average 6.16 years) before diagnosis. Using this dataset, we found a positive but non-significant association between PBL IGF2 hypermethylation and an increased CRC risk. To account for reverse causality, we repeated the analyses excluding subjects who developed CRC within two years after their blood sampling and found that this positive association remained significant (PS-adjusted OR, 2.08, 95% CI: 1.18-3.69; *P*=0.012). Furthermore, our main finding was verified using the GSE89093 dataset. Finally, we pooled the results from these three datasets and found a 2.19-fold higher risk of developing CRC in the IGF2 hypermethylation group compared to the hypomethylation group. The exact mechanism that links alterations in the IGF2 methylation status in PBLs and the

susceptibility for CRC remains unclear. The PBL-derived DNA methylation profiles represent the

overall methylation status of an individual. Alterations in PBL-derived DNA may be constitutively present before cancer occurs or represent an early response of the haematology system to the presence of tumour cells after cancer develops. Imprinting of IGF2 is primarily maintained by DNA 354 methylation.<sup>[30 31]</sup> It has been reported that imprinting and expression are controlled by CpG-rich regions upstream of the IGF2 promotors. Normally, IGF2 is expressed from the paternal allele only, while the maternal allele is methylated and imprinted. Several previous studies have reported that the loss of imprinting (LOI) of IGF2 in peripheral blood (leukocytes or lymphocytes) may be a potential 358 biomarker for the risk of developing  $CRC$ ,  $^{[12\,32]}$  and IGF2 methylation alterations were suggested as 359 a surrogate marker for LOI of IGF2.<sup>[32 33]</sup> If IGF2 aberrant methylation is merely a surrogate marker for LOI of IGF2, then IGF2 hypermethylation would be expected to be beneficial for maintaining the imprinting status of IGF2 and thus should decrease the risk of developing CRC. On the contrary, our results showed that IGF2 hypermethylation increases the risk of developing CRC, indicating that IGF2 participates in CRC tumorigenesis through two different modes of epigenetic alteration, 364 aberrant hypermethylation and LOI, which is supported by previous studies.<sup>[34 35]</sup> Thus, our findings demonstrate that aberrant IGF2 hypermethylation can be assayed with a blood-based test and that the PBL IGF2 methylation status is likely to be a valuable predictive biomarker for CRC risk, independent of LOI of IGF2.

Further analysis of the GEO and TCGA datasets provided additional evidence supporting the association between IGF2 hypermethylation and the risk of developing CRC. For example, using these datasets we found significant associations between IGF2 hypermethylation in tissues and an increased risk of CRC or adenomas (**Figures 8A-D**). Interestingly, colorectal adenomas, a precancerous condition, showed similar levels of IGF2 methylation compared to tumour tissues (**Figure 8E**). Most colorectal cancers initially develop as benign precursor lesions (adenomas) that can take as long as 10 to 15 years to develop into carcinomas, which underpins early detection and 375 removal of adenomas as an important strategy for preventing CRC.<sup>[636]</sup> The findings from the GEO

#### It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.27.22274374;](https://doi.org/10.1101/2022.04.27.22274374) this version posted April 28, 2022. The copyright holder for this preprint



sensitivity analysis again showed a statistically significant association between IGF2

hypermethylation and CRC risk (OR, 1.75, 95% CI: 1.15-2.66; *P*=0.009).

For the first time, we assessed the prognostic value of PBL IGF2 methylation status in CRC patients and found that patients with IGF2 hypermethylation in PBLs had significantly improved survival compared to patients with IGF2 hypomethylation. These findings were especially obvious for stage I-III CRC patients. However, this association did not reach statistical significance in the external EPIC-Italy CRC cohort. Given these inconsistent results, further cohorts with large sample size are needed to validate this novel finding.

For sensitivity analysis, we also evaluated the association between PBL IGF2 methylation and CRC prognosis during different follow-up periods. We observed a significantly strong association for 5-year relative survival, while the associations for both 1-year and 3-year relative survival were not statistically significant. Based on these results, it is hypothesised that the beneficial effects of IGF2 hypermethylation on CRC survival might begin the fifth year following CRC diagnosis and might persist for several years. In fact, the potentially beneficial effects may occur as early as the first year

after CRC diagnosis, even though this effect did not reach statistical significance. The limited sample size of the cohort study may hinder the interpretation of these results; therefore, larger cohort studies are required to further evaluate this issue.

We also evaluated the impact of IGF2 methylation in tumour tissues on CRC patient survival and found no statistically significant association in both our initial cohort and the TCGA datasets. 406 This is in consistent with a recent research.<sup>[7]</sup> However, two previous studies from Japan have assessed the IGF2 methylation status in tumour tissues of CRC patients and the results were 408 inconsistent.<sup>[13 37]</sup> The region tested in those two studies is different from that examined in our study. The lack of consistency between the results from the PBL samples and tumour tissues may reflect the fact that IGF2 methylation is merely a predictive marker rather than a prognostic marker. In addition, the detection of tissue-based markers depends on material from a biopsy or tumour tissue from resection. Because of intratumour heterogeneity, the detection of a biomarker from a single biopsy or one section of a tumour tissue sample might not necessarily represent the IGF2 methylation status of a given patient. Repeated biopsies and tests of multiple samples, however, are not feasible in routine clinical practice. Fortunately, blood-derived biomarkers have the potential to overcome these problems. In this respect, repeat blood sampling and detection of PBL IGF2 methylation is more acceptable and feasible than repeat biopsies in the clinic. Given that CRC has a wide range of long-term outcomes, PBL IGF2 methylation, as a DNA-based non-invasive blood test, could prove beneficial during follow-up and help identify patients at high risk of disease recurrence and progression.

An important aspect and potential concern of using PBL DNA methylation as a biomarker is whether leukocyte subpopulations affect the methylation signature of an individual. To address this concern, we collected patient clinical records including leukocyte counts and included these data as covariates in the PS model. Theoretically, the PS adjustment would control for the potential impact of different leukocyte counts and different subpopulations on our results. We compared the results

before and after including the leukocyte count data in the PS model and found similar results (**Supplementary File 6**), suggesting that the effect of leukocyte counts and subpopulations on our results is negligible. Additional evidence supporting these findings can be found in several recently published studies which also showed that differences in leukocyte subpopulations were unlikely to 430 interfere with the results of PBL-derived DNA methylation.<sup>[38 39]</sup>

Interestingly, our data indicates that PBL IGF2 hypermethylation correlates with serum CEA levels before surgery. Therefore, we further assessed whether the association between PBL IGF2 methylation and CRC prognosis is impacted by CEA levels. Using the additive model, we found a positive interaction between PBL IGF2 methylation and CEA on CRC prognosis (**Figure 9**). Given the limited sample size of the subgroups, this aspect should be further validated in future studies. Of note, after adjustment for CEA and the interaction between IGF2 methylation and CEA, the effect of IGF2 hypermethylation itself on CRC prognosis remained statistically significant (HR, 0.44, 95% CI: 0.24-0.79; *P*=0.006), suggesting a robust and independent role for PBL IGF2 hypermethylation in predicting the prognosis of CRC.

This study has several strengths. The findings from our initial studies were validated with several external datasets. In our initial CRC patient cohort, the covariates were collected prospectively and were blinded to patient outcome. We used PS techniques to control for multiple potential confounding factors. Furthermore, we performed extensive sensitivity analyses to assess the robustness of our findings. The confounding RR and the E-value sensitivity analyses demonstrated that our results are unlikely to be substantially impacted by both the adjusted confounders included in the PS models or a potential residual confounder.

In our present cohort, adjuvant chemotherapy was not offered routinely to high risk individuals. Thus, we did not analyse the clinical significance of IGF2 methylation as a predictive biomarker for sensitivity to adjuvant chemotherapy. Further studies are needed to explore and clarify this issue. Another potential limitation is the limited sample size used in the stratified analyses. Therefore, the

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.27.22274374;](https://doi.org/10.1101/2022.04.27.22274374) this version posted April 28, 2022. The copyright holder for this preprint

results from the stratified analyses should be interpreted with caution.

# **5. CONCLUSIONS**

- In summary, IGF2 methylation in PBLs is significantly associated with the risk and prognosis of
- CRC, suggesting an important role for IGF2 methylation as a blood-based predictive biomarker to
- identify of individuals at high risk of developing CRC; meanwhile, PBL IGF2 methylation might
- also serve as a predictive biomarker for CRC prognosis.

#### **REFERENCES**

- 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021;71:209-49.
- 2. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer.

https://gco.iarc.fr/today/home (Accessed November 7, 2021).

- 3. Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. *Chin Med J (Engl)* 2021;134:783-91.
- 4. Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. *Lancet* 2019;394:1467-80.
- 5. Jones PA, Baylin SB. The epigenomics of cancer. *Cell* 2007;128:683-92.
- 6. Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal cancer. *Nat Rev Dis Primers* 2015;1:15065.
- 7. Hidaka H, Higashimoto K, Aoki S, et al. Comprehensive methylation analysis of imprinting-associated differentially methylated regions in colorectal cancer. *Clin Epigenetics* 2018;10:150.
- 8. Unger C, Kramer N, Unterleuthner D, et al. Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms. *Oncogene* 2017;36:5341-55.
- 9. Rogers MA, Kalter V, Strowitzki M, et al. IGF2 knockdown in two colorectal cancer cell lines decreases survival, adhesion and modulates survival-associated genes. *Tumour Biol* 2016;37:12485-95.
- 10. Bergman D, Halje M, Nordin M, et al. Insulin-like growth factor 2 in development and disease: a mini-review. *Gerontology* 2013;59:240-9.
- 11. Cheng YW, Idrees K, Shattock R, et al. Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer. *Int J Cancer* 2010;127:568-77.
- 12. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. *Science* 2003;299:1753-5.
- 13. Baba Y, Nosho K, Shima K, et al. Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. *Gastroenterology* 2010;139:1855-64.
- 14. Elze MC, Gregson J, Baber U, et al. Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. *J Am Coll Cardiol* 2017;69:345-57.
- 15. Haukoos JS, Lewis RJ. The Propensity Score. *JAMA* 2015;314:1637-8.
- 485 16. Gene Expression Omnibus. Available at: https://www.ncbi.nlm.nih.gov/geo/. Accessed May 22, 2020.
- 17. Cordero F, Ferrero G, Polidoro S, et al. Differentially methylated microRNAs in prediagnostic samples of subjects who developed breast cancer in the European Prospective Investigation into Nutrition and Cancer (EPIC-Italy) cohort. *Carcinogenesis* 2015;36:1144-53.



## **Figures**

- **Figure 1.** Flow chart of participants included and analysed in the (**A**) initial and (**B**) validation
- studies. COAD, colon adenocarcinoma; CRC, colorectal cancer; EPIC-Italy, the European
- Prospective Investigation into Cancer and nutrition (EPIC cohort) in Italy; GEO, Gene Expression
- Omnibus; READ, rectum adenocarcinoma; TCGA, The Cancer Genome Atlas.
- 



It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.27.22274374;](https://doi.org/10.1101/2022.04.27.22274374) this version posted April 28, 2022. The copyright holder for this preprint

- **Figure 2.** MS-HRM assay to detect methylation levels at the IGF2 promoter region. Our assay encompassed a 101 bp region (range: chr11: 2139870-2139971, including 11 CpGs), which located in the promoter of human IGF2 gene and near the transcription start site (TSS). Arrows indicate position and direction of MS-HRM primers. **Black dashes ( )** indicate individual CpGs on DMR region tested in our study. **Black Dots ( )** indicate six methylation probes (including cg17434309, cg05859777, cg01667319, cg05452899, cg10037494, cg26517849) on the Illumina Infinium HumanMethylation450 BeadChip, which overlap CpG 545 sites detected in our DMR region. \*The TSS±1500 region is an expanded region of -1500 bp upstream to +1500 downstream from the TSS (range: chr11: 2137890-2140889). To test the robustness of our results, we further assess the association of methylation levels of this expanded region with CRC risk. In the TSS±1500 region, a total of 32 CpG sites were detected by the Infinium HumanMethylation450 methylation probes. The methylation probes are as follows: cg25163476, cg24917382, cg24366657, cg23905216, cg23676551, cg22287492, cg21667878, cg20339650, cg19443075, cg19371526, cg19002337, cg18087943, cg17434309, cg17037101, cg16415340, cg15393937, cg14608156, cg14188639, cg13756879, cg12773325, cg12614029, cg11915650, cg10659464, cg10037494, cg09694722, cg08162473, cg05859777, cg05452899, cg04072545, cg03760951, cg02835822, cg01667319.
- 

# IGF<sub>2</sub>



23

- 556 **Figure 3.** The results for the association between PBL IGF2 methylation and the risk of developing CRC (**A**) in the initial and validation
- 557 studies, and (**B**) in the combined populations.
- 558 \*A total of 14 covariates were included in the propensity score model in the initial case-control study (see supplementary table S3). In the
- 559 validation studies, gender and age were included in the the propensity score model for GSE51032 and age for GSE89093, respectively.
- 560 To be conservative, we pooled the results from these three datasets with a random effect model in the meta-analysis. BMI, body mass
- 561 index; CI, confidence interval; Hyper-, IGF2 hypermethylation; Hypo-, IGF2 hypomethylation; OR, odds ratio.
	- A

562



В

**Study** 



It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.27.22274374;](https://doi.org/10.1101/2022.04.27.22274374) this version posted April 28, 2022. The copyright holder for this preprint

**Figure 4.** IGF2 methylation in PBLs and CRC prognosis in the initial cohort. Kaplan-Meier plots for

- (**A**) overall survival, (**B**) CRC specific survival, and (**C**) disease-free survival according to IGF2
- methylation status in PBLs in CRC patients. (**D**) Associations of *IGF2* methylation in PBLs with
- CRC prognosis during different follow-up periods. CI, confidence interval; CRC, colorectal cancer;
- CSS, cancer specific survival; DFS, disease free survival; HR, hazard ratio; Hyper-, IGF2
- hypermethylation; Hypo- IGF2 hypomethylation; OS, overall survival; PBL, peripheral blood
- leukocyte.



- **Figure 5.** Kaplan-Meier curves for IGF2 methylation in PBLs and CRC overall survival in the
- EPIC-Italy cohort. CI, confidence interval; HR, hazard ratio; Hyper-, IGF2 hypermethylation; Hypo-
- IGF2 hypomethylation.



- **Figure 6.** The association between IGF2 methylation in tumour tissues and CRC patient prognosis.
- Kaplan-Meier curves for overall survival according to IGF2 methylation status in tumour tissues of
- CRC patients in (**A**) the initial cohort and (**B**) TCGA datasets. (**C**) The correlation between IGF2
- mRNA expression level and methylation level of the differentially methylated region of IGF2 tested
- in our study using the TCGA dataset. (**D**) Kaplan-Meier curves for overall survival according to
- IGF2 mRNA expression levels in tumour tissues of CRC patients in the TCGA cohort.
- CI, confidence interval; CRC, colorectal cancer; HR, hazard ratio.



- **Figure 7.** Sensitivity analyses using the confounding RR method. The confounding RR was defined as the ratio of the PS-adjusted effect estimates and the unadjusted effect estimates.
- CI, confidence interval; CRC, colorectal cancer; CSS, cancer specific survival; DFS, disease free
- survival; HR, hazard ratio; OR, odds ratio; OS, overall survival; PS, propensity score.



**Figure 8.** The associations between IGF2 methylation in tissue samples and CRC risk in the datasets from GEO and TCGA. (**A**) Adenoma or tumour

tissues versus normal colorectal mucosa in the GEO datasets. (**B**) Tumour tissues versus normal colorectal mucosa in the TCGA datasets. (**C**) Tumour

tissues versus matched adjacent normal tissues in the datasets from (**C**) GEO and (**D**) TCGA. (**E**) The discrimination performance of IGF2 methylation

in tissue samples to identify CRC tumour or adenoma tissue and normal colorectal mucosa in the datasets from GEO and TCGA. (**F**) The IGF2 methylation levels in normal colorectal mucosa, adenoma and tumour tissue samples in the GEO datasets. \*indicates *P*<0.0001, and ns indicates not

statistical significance. AUC, the area under receiver operating characteristic curves; CI, confidence interval; OR, odds ratio; Hyper-, IGF2

hypermethylation; Hypo-, IGF2 hypomethylation;



It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.27.22274374;](https://doi.org/10.1101/2022.04.27.22274374) this version posted April 28, 2022. The copyright holder for this preprint

**Figure 9.** The interaction between PBL IGF2 methylation and serum CEA levels on CRC patient

prognosis using the additive and multiplicative models. (**A**) The interaction analysed with the

additive model. (**B**) The effect estimates for interaction in respected to both the additive and

- multiplicative models. AP, attributable proportion due to interaction; CI, confidence interval; HR,
- hazard ratio; Hyper-, IGF2 hypermethylation; Hypo-, IGF2 hypomethylation; PBL, peripheral blood
- leukocyte; RERI, relative excess risk due to interaction; SI, synergy index; V index, the
- multiplicative interaction index.





B





#### 607 **Table 1.** Subgroup analysis for the association of PBL IGF2 methylation with CRC prognosis.

<sup>\*</sup>Test for heterogeneity between ORs was conducted by using random effect models with Comprehensive Meta

609 Analysis (version 2.2.046). BMI, body mass index; CI, confidence interval; CRC, colorectal cancer; CSS, cancer

610 specific survival; DFS, disease free survival; HR, hazard ratio; OS, overall survival; PBL, peripheral blood leukocyte;

611 PS, propensity score.

# **Supplementary Files**

- Supplementary File 1A. Main characteristics of participants of the initial and validation studies in the
- CRC risk analysis.
- Supplementary File 1B. Main characteristics of patients of the initial and validation cohorts in the CRC
- prognosis analysis.
- Supplementary File 2A. Comparisons of participant characteristics and covariates between CRC cases
- and controls before and after propensity score adjustment in the initial case-control study in CRC risk
- analysis.
- Supplementary File 2B. Comparisons of baseline characteristics of CRC patients before and after
- propensity score adjustment in the initial cohort in CRC prognosis analysis.
- Supplementary File 3A. Sensitivity analyses using additional propensity score based methods for CRC
- risk analysis in the initial case-control study.
- Supplementary File 3B. Sensitivity analyses using additional propensity score based methods for CRC
- survival analysis in the initial CRC cohort.
- Supplementary File 4. E-values for PS-adjusted effect estimates.
- Supplementary File 5. Associations between PBL IGF2 methylation status and UICC stage, serum CEA
- level, WBC counts, and whether or not included in the survival analysis among CRC patients.
- Supplementary File 6. Associations of PBL IGF2 methylation and CRC patient prognosis with or
- without WBC counts included in PS models.

The EPIC-Italy Cohort (**n=166**) **Blood Samples** 

**Tissue Samples** 



![](_page_31_Figure_3.jpeg)

# *IGF2*

![](_page_32_Figure_1.jpeg)

![](_page_33_Picture_527.jpeg)

![](_page_33_Figure_2.jpeg)

**A**

![](_page_34_Figure_0.jpeg)

![](_page_34_Figure_1.jpeg)

![](_page_35_Figure_0.jpeg)

Survival Time (days)

![](_page_36_Figure_0.jpeg)

![](_page_37_Figure_0.jpeg)

![](_page_38_Figure_4.jpeg)

![](_page_38_Figure_1.jpeg)

![](_page_38_Figure_3.jpeg)

**A**

**B**

![](_page_39_Figure_0.jpeg)

# **B**

![](_page_39_Picture_175.jpeg)

**A**